{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:12Z","timestamp":1788401592261,"version":"build-2803163510"},"reference-count":38,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Young people undergoing cancer treatment are at increased risk of severe COVID-19 outcomes. Vaccination is recommended; however, data regarding vaccine response are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A prospective cohort study was conducted of children and adolescents (aged 5\u201319\u00a0years) with current solid or hematological cancer and life expectancy of at least 1\u00a0year, eligible for COVID-19 vaccination. Participants received 2 or 3 doses of BNT162b2. Blood was taken at baseline, after dose 1, and then 1 and 3\u00a0months after subsequent doses. Safety outcomes and patient-reported adverse events were collected. The proportion with neutralizing antibody (NAb) response after 2 vaccine doses was the primary outcome. Vaccine response was measured by NAb titer (positive \u22651:20), T-cell response (interferon-\u03b3, positive \u226510 pg\/mL), and binding antibody titer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 113 patients enrolled, 108 (96%) currently or previously received cytotoxic chemotherapy, and most were on current or recent therapy, with 18 (16%) having completed treatment more than 6\u00a0months prior to vaccination. Positive NAb response occurred in 52\/79 (66%) with samples available after 2 doses and 33\/41 (80%) after 3 doses. Interferon-\u03b3 response occurred in 44\/64 (59%) after 2 doses and 25\/34 (74%) after 3 doses. Adverse events were generally mild to moderate, were transient if serious (fever, mucositis, headache), and did not delay cancer treatment. Fever was reported by 12% after doses 1 and 2 and 15% after dose 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Most children with cancer respond to BNT162b2 COVID-19 vaccination despite anticancer treatment. Vaccination should not be deferred until treatment completion. These data may have implications for other childhood vaccinations during cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1542\/peds.2024-070209","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:02:28Z","timestamp":1754611348000},"source":"Crossref","is-referenced-by-count":3,"title":["Immune Response to COVID-19 Vaccination in Children With Cancer"],"prefix":"10.1542","volume":"156","author":[{"given":"Amy","family":"Body","sequence":"first","affiliation":[{"name":"1Monash Health, Department of Oncology, Clayton, VIC, Australia"},{"name":"2Monash University, Sub-Faculty of Clinical and Molecular Medicine, Department of Medicine, Nursing and Health Sciences, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxi","family":"Lal","sequence":"additional","affiliation":[{"name":"1Monash Health, Department of Oncology, Clayton, VIC, Australia"},{"name":"2Monash University, Sub-Faculty of Clinical and Molecular Medicine, Department of Medicine, Nursing and Health Sciences, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Downie","sequence":"additional","affiliation":[{"name":"1Monash Health, Department of Oncology, Clayton, VIC, Australia"},{"name":"2Monash University, Sub-Faculty of Clinical and Molecular Medicine, Department of Medicine, Nursing and Health Sciences, Melbourne, VIC, Australia"},{"name":"3Monash Children\u2019s Hospital, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Anazodo","sequence":"additional","affiliation":[{"name":"4Children\u2019s Cancer Institute, Lowy Cancer Centre, University of New South Wales, Kensington, NSW, Australia"},{"name":"5Kids Cancer Centre, Sydney Children\u2019s Hospital, Randwick, NSW, Australia"},{"name":"6School of Clinical Medicine, UNSW Medicine & Health, University of New South Wales, Kensington, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"5Kids Cancer Centre, Sydney Children\u2019s Hospital, Randwick, NSW, Australia"},{"name":"6School of Clinical Medicine, UNSW Medicine & Health, University of New South Wales, Kensington, NSW, Australia"},{"name":"7Cancer Institute NSW, St Leonards, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavna","family":"Padhye","sequence":"additional","affiliation":[{"name":"8Cancer Centre for Children at The Children\u2019s Hospital at Westmead, Westmead, NSW, Australia"},{"name":"9Kids Research, Children\u2019s Cancer Research Unit, The Children\u2019s Hospital at Westmead, Westmead, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Fuentes-Bolanos","sequence":"additional","affiliation":[{"name":"4Children\u2019s Cancer Institute, Lowy Cancer Centre, University of New South Wales, Kensington, NSW, Australia"},{"name":"5Kids Cancer Centre, Sydney Children\u2019s Hospital, Randwick, NSW, Australia"},{"name":"6School of Clinical Medicine, UNSW Medicine & Health, University of New South Wales, Kensington, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriganesh","family":"Srihari","sequence":"additional","affiliation":[{"name":"10Queensland Institute of Medical Research Berghofer, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Stephanie Ahern","sequence":"additional","affiliation":[{"name":"1Monash Health, Department of Oncology, Clayton, VIC, Australia"},{"name":"2Monash University, Sub-Faculty of Clinical and Molecular Medicine, Department of Medicine, Nursing and Health Sciences, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Haber","sequence":"additional","affiliation":[{"name":"4Children\u2019s Cancer Institute, Lowy Cancer Centre, University of New South Wales, Kensington, NSW, Australia"},{"name":"6School of Clinical Medicine, UNSW Medicine & Health, University of New South Wales, Kensington, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Smith","sequence":"additional","affiliation":[{"name":"11QIMR Berghofer Translational and Human Immunology Laboratory, Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia"},{"name":"12Queensland Immunology Research Centre, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Lineburg","sequence":"additional","affiliation":[{"name":"11QIMR Berghofer Translational and Human Immunology Laboratory, Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia"},{"name":"12Queensland Immunology Research Centre, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Turville","sequence":"additional","affiliation":[{"name":"13Kirby Institute, University of New South Wales, Sydney, NSW, Australia"},{"name":"14University of Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin","family":"Naing","sequence":"additional","affiliation":[{"name":"15Serology and Virology Division (SAViD), NSW Health Pathology East, Department of Microbiology, Prince of Wales Hospital, Randwick, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rawlinson","sequence":"additional","affiliation":[{"name":"15Serology and Virology Division (SAViD), NSW Health Pathology East, Department of Microbiology, Prince of Wales Hospital, Randwick, Sydney, NSW, Australia"},{"name":"16Virology Research Laboratory, Prince of Wales Hospital, Randwick, Sydney, NSW, Australia"},{"name":"17School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Buttery","sequence":"additional","affiliation":[{"name":"18University of Melbourne, Child Health Informatics (Paediatrics), Melbourne, VIC, Australia"},{"name":"19Royal Children\u2019s Hospital, Melbourne, VIC, Australia"},{"name":"20Murdoch Children\u2019s Research Institute, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Raina MacIntyre","sequence":"additional","affiliation":[{"name":"21Biosecurity Program, Kirby Institute, University of New South Wales, Sydney, NSW, Australia"},{"name":"22School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia"},{"name":"23National Centre for Immunization, Research and Surveillance of Vaccine Preventable Diseases, University of Sydney, Westmead, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienne","family":"Milch","sequence":"additional","affiliation":[{"name":"24Cancer Australia, Sydney, NSW, Australia"},{"name":"25Caring Futures Institute, Flinders University, Adelaide, SA, Australia"},{"name":"26School of Medicine, The University of Notre Dame Australia, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Segelov","sequence":"additional","affiliation":[{"name":"2Monash University, Sub-Faculty of Clinical and Molecular Medicine, Department of Medicine, Nursing and Health Sciences, Melbourne, VIC, Australia"},{"name":"27University of Bern, Department of Clinical Research (Medicine), Bern, Switzerland"},{"name":"28Department of Radiation Oncology, University Cancer Centre, Inselspital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"issue":"4","key":"2026050605373070200_r1","first-page":"315","article-title":"Recent progress in the treatment of cancer in children","volume":"71","author":"Butler","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"4","key":"2026050605373070200_r2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s43018-023-00540-z","article-title":"Harnessing immune checkpoint trial data in pediatric cancer","volume":"4","author":"Neeson","year":"2023","journal-title":"Nature Cancer."},{"issue":"11","key":"2026050605373070200_r3","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","article-title":"Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer","volume":"26","author":"Wong","year":"2020","journal-title":"Nature Medicine."},{"issue":"5","key":"2026050605373070200_r4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/pbc.20018","article-title":"Immunologic monitoring of maintenance therapy for acute lymphoblastic leukaemia in children-preliminary report","volume":"42","author":"Luczynski","year":"2004","journal-title":"Pediatr Blood Cancer."},{"issue":"34","key":"2026050605373070200_r5","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO.21.00702","article-title":"SARS-CoV-2 in childhood cancer in 2020: a disease of disparities","volume":"39","author":"Johnston","year":"2021","journal-title":"J Clin Oncol."},{"issue":"10","key":"2026050605373070200_r6","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/S1470-2045(21)00454-X","article-title":"Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study","volume":"22","author":"Mukkada","year":"2021","journal-title":"Lancet Oncol."},{"issue":"4","key":"2026050605373070200_r7","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/infdis\/jiad496","article-title":"SARS-CoV-2 infection in the pediatric oncology population: the definitive comprehensive report of the Infectious Diseases Working Group of AIEOP","volume":"229","author":"Zama","year":"2024","journal-title":"J Infect Dis."},{"issue":"12","key":"2026050605373070200_r8","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/OP.23.00631","article-title":"COVID-19 disease in children with ALL receiving maintenance therapy: do not discount the risk","volume":"20","author":"Kahn","year":"2024","journal-title":"JCO Oncol Pract."},{"issue":"6","key":"2026050605373070200_r9","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.31557\/APJCP.2022.23.6.2049","article-title":"Immune response after 2 doses of BNT162b2 mRNA COVID-19 vaccinations in children and adolescents with cancer and hematologic diseases","volume":"23","author":"Poparn","year":"2022","journal-title":"Asian Pac J Cancer Prev."},{"issue":"2","key":"2026050605373070200_r10","doi-asserted-by":"crossref","first-page":"e30785","DOI":"10.1002\/pbc.30785","article-title":"SARS-CoV-2 vaccination response in pediatric oncology patients","volume":"71","author":"D\u2019Souza","year":"2024","journal-title":"Pediatr Blood Cancer."},{"issue":"9","key":"2026050605373070200_r11","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.3390\/cancers15092562","article-title":"Immune response following BNT162b2 mRNA COVID-19 vaccination in pediatric cancer patients","volume":"15","author":"Schmidt","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"8","key":"2026050605373070200_r12","doi-asserted-by":"crossref","first-page":"e30473","DOI":"10.1002\/pbc.30473","article-title":"Humoral profiling of pediatric patients with cancer reveals robust immunity following anti-SARS-CoV-2 vaccination superior to natural infection","volume":"70","author":"Martin","year":"2023","journal-title":"Pediatr Blood Cancer."},{"key":"2026050605373070200_r13","doi-asserted-by":"crossref","first-page":"1110755","DOI":"10.3389\/fimmu.2023.1110755","article-title":"Reduced humoral response against variants of concern in childhood solid cancer patients compared to adult patients and healthy children after SARS-CoV-2 vaccination","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol."},{"issue":"3","key":"2026050605373070200_r14","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1093\/cid\/ciac570","article-title":"Longitudinal immune response to 3 doses of messenger RNA vaccine against coronavirus disease 2019 (COVID-19) in pediatric patients receiving chemotherapy for cancer","volume":"76","author":"Lehrnbecher","year":"2023","journal-title":"Clin Infect Dis."},{"issue":"4","key":"2026050605373070200_r15","first-page":"221","article-title":"Pediatric cancer patients vaccinated against SARS-CoV-2\u2014a clinical and laboratory follow-up","volume":"32","author":"Siebald","year":"2024","journal-title":"Support Care Cancer."},{"issue":"4","key":"2026050605373070200_r16","doi-asserted-by":"crossref","first-page":"e31572","DOI":"10.1002\/pbc.31572","article-title":"COVID-19 vaccine response in pediatric oncology patients","volume":"72","author":"Kam","year":"2025","journal-title":"Pediatr Blood Cancer."},{"key":"2026050605373070200_r17","article-title":"ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5\u201311\u00a0years","author":"Australian Technical Advisory Group on Immunisation (ATAGI)","year":"2022"},{"key":"2026050605373070200_r18","article-title":"ATAGI recommendations on first booster dose in adolescents aged 12\u201315\u00a0years","author":"Australian Technical Advisory Group on Immunisation (ATAGI)","year":"2022"},{"issue":"4","key":"2026050605373070200_r19","doi-asserted-by":"crossref","first-page":"e0019322","DOI":"10.1128\/msphere.00193-22","article-title":"The Serological Sciences Network (SeroNet) for COVID-19: depth and breadth of serology assays and plans for assay harmonization","volume":"7","author":"Karger","year":"2022","journal-title":"MSphere."},{"key":"2026050605373070200_r20","doi-asserted-by":"crossref","first-page":"126547","DOI":"10.1016\/j.vaccine.2024.126547","article-title":"Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer","volume":"46","author":"Body","year":"2025","journal-title":"Vaccine."},{"issue":"1","key":"2026050605373070200_r21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12879-021-07019-1","article-title":"Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)","volume":"22","author":"Body","year":"2022","journal-title":"BMC Infect Dis."},{"issue":"7","key":"2026050605373070200_r22","doi-asserted-by":"crossref","first-page":"e1003656","DOI":"10.1371\/journal.pmed.1003656","article-title":"SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants","volume":"18","author":"Tea","year":"2021","journal-title":"PLoS Med."},{"issue":"7","key":"2026050605373070200_r23","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med."},{"issue":"1","key":"2026050605373070200_r24","doi-asserted-by":"crossref","first-page":"10517","DOI":"10.1038\/s41598-022-14351-2","article-title":"The influence of time on the sensitivity of SARS-CoV-2 serological testing","volume":"12","author":"Torres Ortiz","year":"2022","journal-title":"Sci Rep."},{"issue":"12","key":"2026050605373070200_r25","doi-asserted-by":"crossref","first-page":"e1219","DOI":"10.1002\/cti2.1219","article-title":"Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases","volume":"9","author":"Lineburg","year":"2020","journal-title":"Clin Transl Immunology."},{"key":"2026050605373070200_r26","article-title":"SeroNet Resources for Researchers and Clinicians","author":"Center for Strategic Scientific Initiatives (CSSI)"},{"key":"2026050605373070200_r27"},{"issue":"12","key":"2026050605373070200_r28","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s43018-021-00274-w","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat Cancer."},{"key":"2026050605373070200_r29","article-title":"COVID-19 Australia: Epidemiology Report 58","volume-title":"Commun Dis Intell (2018).","author":"COVID-19 National Incident Room Surveillance Team","year":"2022"},{"issue":"1","key":"2026050605373070200_r30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41467-021-27674-x","article-title":"Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts","volume":"13","author":"Kundu","year":"2022","journal-title":"Nat Commun."},{"key":"2026050605373070200_r31","author":"Melbourne Vaccine Education Centre","year":"2022"},{"issue":"3","key":"2026050605373070200_r32","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis."},{"issue":"3","key":"2026050605373070200_r33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2352-4642(22)00315-7","article-title":"Lessons learnt from influenza vaccination in immunocompromised children undergoing treatment for cancer","volume":"7","author":"Furlong","year":"2023","journal-title":"Lancet Child Adolesc Health."},{"key":"2026050605373070200_r34","article-title":"Vaccinations for paediatric patients treated with standard-dose chemotherapy and haemopoietic stem cell transplantation (HSCT) recipients","author":"Patel","year":"2023"},{"issue":"4","key":"2026050605373070200_r35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"2026050605373070200_r36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11\u00a0years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med."},{"key":"2026050605373070200_r37","first-page":"77","article-title":"Australia\u2019s Children (Australian Government)","author":"Australian Institute of Health and Welfare","year":"2020"},{"key":"2026050605373070200_r38","article-title":"Cancer data in Australia","author":"Australian Institute of Health and Welfare"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-070209\/1840425\/pediatrics.2024070209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-070209\/1840425\/pediatrics.2024070209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:37:44Z","timestamp":1778060264000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/156\/3\/e2024070209\/203030\/Immune-Response-to-COVID-19-Vaccination-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,8]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2024-070209","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"e2024070209"}}